News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
FDA
Pfizer Inc.'s Drug for Nerve Pain, Lyrica Gets Expanded Approval In Japan
October 29, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Oct 28 (Reuters) - Japanese health regulators approved Pfizer Inc's (PFE.N) Lyrica to treat a type of nerve pain called peripheral neuropathic pain, Pfizer said on Thursday.
Twitter
LinkedIn
Facebook
Email
Print
FDA
Approvals
Asia
Pfizer
MORE ON THIS TOPIC
FDA
Compass vows to press on with FDA application despite new trial request
September 22, 2026
·
3 min read
·
Annalee Armstrong
Manufacturing
Western licensing deals for Chinese radioligand therapies to jump in 2027, Sleuth forecasts
September 21, 2026
·
2 min read
·
Nick Paul Taylor
Rare diseases
Mikhail, Davis on board with regulatory framework tailored to rare disease therapies
September 21, 2026
·
6 min read
·
Heather McKenzie
China
China plans to transform biotech sector into $522B powerhouse by 2030
September 18, 2026
·
2 min read
·
Annalee Armstrong
